Currently Viewing:
The American Journal of Managed Care November 2014
The Correlation of Family Physician Work With Submitted Codes and Fees
Richard Young, MD, and Tiffany L. Overton, MPH
Population Targeting and Durability of Multimorbidity Collaborative Care Management
Elizabeth H.B. Lin, MD, MPH; Michael Von Korff, ScD; Do Peterson, MS; Evette J. Ludman, PhD; Paul Ciechanowski, MD, MPH; and Wayne Katon, MD
Have Prescription Drug Brand Names Become Generic?
Alfred B. Engelberg, JD
Will Medicare Advantage Payment Reforms Impact Plan Rebates and Enrollment?
Lauren Hersch Nicholas, PhD, MPP
Variation in Hospital Inpatient Prices Across Small Geographic Areas
Jared Lane K. Maeda, PhD, MPH; Rachel Mosher Henke, PhD; William D. Marder, PhD; Zeynal Karaca, PhD; Bernard S. Friedman, PhD; and Herbert S. Wong, PhD
Medical Cost Burdens Among Nonelderly Adults With Asthma
Emily Carrier, MD, and Peter Cunningham, PhD
The Role of Retail Pharmacies in CVD Prevention After the Release of the ATP IV Guidelines
William H. Shrank, MD, MSHS; Andrew Sussman, MD; and Troyen A. Brennan, MD, JD
Care Coordination Measures of a Family Medicine Residency as a Model for Hospital Readmission Reduction
Wayne A. Mathews, MS, PA-C
Currently Reading
Medication Adherence and Readmission After Myocardial Infarction in the Medicare Population
Yuting Zhang, PhD; Cameron M. Kaplan, PhD; Seo Hyon Baik, PhD; Chung-Chou H. Chang, PhD; and Judith R. Lave, PhD
Switching from Multiple Daily Injections to CSII Pump Therapy: Insulin Expenditures in Type 2 Diabetes
Guy David, PhD; Max Gill, MBA, Candace Gunnarsson, EdD; Jeff Shafiroff, PhD; and Steven Edelman, MD
Service Setting Impact on Costs for Bevacizumab-Treated Oncology Patients
Nicole M. Engel-Nitz, PhD; Elaine B. Yu, PharmD, MS; Laura K. Becker, MS; and Art Small, MD
Influence of Hospital and Nursing Home Quality on Hospital Readmissions
Kali S. Thomas, PhD; Momotazur Rahman, PhD; Vincent Mor, PhD; and Orna Intrator, PhD

Medication Adherence and Readmission After Myocardial Infarction in the Medicare Population

Yuting Zhang, PhD; Cameron M. Kaplan, PhD; Seo Hyon Baik, PhD; Chung-Chou H. Chang, PhD; and Judith R. Lave, PhD
Better outpatient medication adherence reduces the likelihood of readmission after a recent myocardial infarction.
To examine the relationship between 6-month medication adherence and 1-year downstream heart disease–related readmission among patients who survived a myocardial infarction (MI).

Study Design
Retrospective, nested case-control analysis of Medicare fee-for-service beneficiaries who were discharged alive post MI in 2008 (n = 168,882).

Patients in the case group had their first heart-disease–related readmission post MI discharge during the 6-to-9-month period or the 9-to-12-month period. We then used propensity score matching to identify patients in the control group who had similar characteristics, but did not have a readmission in the same time window. Adherence was defined as the average 6-month medication possession ratio (MPR) prior to the first date of the time-window defining readmission.

After controlling for demographics, insurance coverage, and clinical characteristics, patients who had a heart-disease–related readmission had worse adherence, with MPRs of 0.70 and 0.74 in the case and control groups, respectively. Odds ratio of MPR ≥0.75 was 0.79 (95% CI, 0.75-0.83) among those with a readmission relative to those without.

Our study shows that better 6-month medication adherence may reduce heart-disease–related readmissions within a year after an MI.

Am J Manag Care. 2014;20(11):e498-e505
This study demonstrates that patients’ good adherence to essential myocardial infarction (MI) medications is a key factor in preventing readmission occurring 6 months to 1 year after discharge, and suggests that clinicians need to pay attention to outpatient medication adherence after inpatient discharge.
  • The probability of having a preventable readmission 6 to 12 months post MI discharge was much lower for beneficiaries with good adherence to all MI drugs compared with those with poor adherence.
  • Outpatient physicians should pay more attention to medication adherence among MI survivors to prevent readmission in the first year after discharge.
According to the American Heart Association, 7.9 million Americans have a history of myocardial infarction (MI) and 450,000 deaths occur each year in the United States because of new and recurrent MIs.1 Readmissions after MIs are common and costly. For example, the rates for 30-day all-cause readmission after an MI from 2006 to 2008 in the Medicare population were 22.5%, 24.8%, and 23% among white, black, and Hispanic patients, respectively.2,3 Previous research on readmissions focused primarily on 30-day all-cause readmission and examined the association between readmissions and hospital-level factors. This focus on 30-day readmissions was stimulated in part due to the Affordable Care Act (ACA), with Congress directing CMS to reduce payments to hospitals with higher than expected 30-day readmission rates. However, as a recent article notes,4 the policy makers’ emphasis on 30-day readmission may be misguided since the majority of readmissions take place outside the 30-day window. Additionally, patient-level factors outside of the hospital’s control may drive a considerable part of hospital readmission rates, especially for longer-term readmission.

One key factor affecting readmission rates is believed to be patients’ compliance with essential medications, including beta-blockers, lipid-lowering agents (statins), aspirin, and (depending on the patient) angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). Because extensive clinical trials have shown these drugs to be very effective, they have become important components of lifelong medical therapy for these patients.5 As a result, clinical guidelines now recommend that patients who survive an acute MI receive these medications.6

Previous studies have shown that better medication adherence could reduce medical spending,7-11 in part due to reduced hospitalization and emergency department use. Both adherence and the likelihood of readmission are time-dependent variables, and we expected that the likelihood of readmissions was influenced more by drug adherence closer in time to the reference point than adherence further in the past.

To resolve the issue of time-dependent variables, we used a retrospective, nested case-control study design to examine the relationship between 6-month adherence following a hospitalization for MI and a subsequent readmission that occurs between 6 and 12 months post MI. This method is commonly used in medicine and health service research, but it has not been used to study adherence and readmission. We hypothesize that patients with better 6-month adherence to essential medications used to treat MI are less likely to have readmissions related to heart disease.


Study Design

The key challenge to studying how adherence affects readmission is that both adherence and the likelihood of readmission are time-dependent variables. For example, to study the effect of 6-month adherence on the readmission rates within 1 year of discharge, we could not have simply compared the 1-year readmission rates among individuals with good or bad 6-month adherence. We needed to ensure that the interval used to measure adherence occurred within a reasonably short period prior to the time we measure readmission, so we could more confidently infer that the adherence affects readmission.

We attempted to address time dependency using a nested case-control design because it allowed us to measure adherence before potential readmission. Specifically, we identified the case group as beneficiaries who had their first heart disease–related readmission during 2 time windows post MI: 6 to 9 months and 9 to 12 months. We chose the follow-up period to be a minimum of 6 months for 2 reasons: first, short-term readmissions (eg, 30-day readmission) are more likely due to hospital factors than to patient medication adherence.12 Second, 6 months is the shortest period to meaningfully measure adherence because prescriptions with a 90-day supply are now common.

We then used propensity score matching to identify the control group: Medicare beneficiaries who had similar characteristics to those in the case group, as measured by observed covariates, but who did not have a readmission in the same time window. For both groups, the main exposure variable (adherence) was defined as the average 6-month medication possession ratio (MPR) prior to the first date of the time window defining readmission. The first heart disease–related readmission day for each beneficiary in the case group was selected as the index date in order to focus the following 2 dates: the start date from which we counted back 6 months to define adherence, and the anchor date for the matched individuals in the control group to define adherence.

Data Source and Case/Control Groups

We used 2008 and 2009 pharmacy and medical claims data for all fee-for-service Medicare beneficiaries with Parts A, B, and D coverage who had an MI in 2008. MI was defined as having at least 1 inpatient claim with a primary or secondary diagnosis code as 410.X1 in International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

We first identified beneficiaries who a) had an MI in 2008 and were discharged alive (the discharge date was defined as discharge index date); b) were enrolled in a standalone Part D plan continuously for 6 months after the discharge index date; and c) had a heart disease–related readmission (primary and secondary ICD-9-CM diagnosis codes 390-459). We excluded patients who were readmitted within the first 6 months after discharge or who died.

Propensity Score Matching Adjustment Variables

To ensure that the case and control groups were comparable, we used propensity score matching. In calculating propensity scores, we first conducted a logistic model with the response variable as having a heart disease–related readmission between 6 and 9 months post discharge; that was the index date (ie, an indicator for case/control groups). In the model, we accounted for individual-level characteristics for demographic, insurance coverage, and health status. The demographic variables included gender, age (by group: aged ≤34 years, 35-50 years, 51-64 years, 65-74 years, 75-84 years, and ≥85 years), and race or ethnic group (non-Hispanic white, non-Hispanic black, Hispanic, Asian, and others/unknown, all relative to white). Part D data have an enhanced Research Triangle Institute Race Code verified by first and last name algorithms, which is much more accurate than the usual race variable found in claims data.13 We also included information on whether the beneficiary qualified for Medicare because of disability.

The data included 2 additional insurance variables: whether the beneficiary had Medicaid (was dual-eligible) and/or received a low-income subsidy (LIS). These 2 variables provide information on the beneficiary’s income as well as the amount of co-payment and premium subsidies they receive. The income of the median dual-eligible is 75% of the federal poverty level (FPL), although there is some variation across states, while the incomes of the beneficiaries in the LIS group are below 150% of the FPL. Thus, the income in the non-LIS group is above 150% of the FPL. However, since the majority of beneficiaries in the LIS group also have some Medicaid coverage, we created 3 mutually exclusive income categories: duals, nondual LIS, and non-LIS.

The health status variables included 2 prospective risk scores: the CMS Hierarchical Condition Category score and the analogous score for prescription drugs. These risk scores were calculated using the diagnoses and spending in the year prior to the discharge index date. We calculated the prospective risk scores using prior year diagnoses, except for the 2.3% of the sample who were new enrollees, for whom we used concurrent risk scores based on age and gender.14 Risk scores represent a proxy for health status, with higher scores indicating greater severity of illness and higher expected healthcare utilization. We included 2 additional health status indicators: one for a history of prior MI and the other for institutionalization, defined as 90 days of care in a nursing home. Our sample represents community-residing beneficiaries; less than 0.1% spent more than 90 days in nursing home facilities. Because Part D data include drugs used in nursing homes, we did not exclude these individuals.

Finally, the model accounted for zip code level income and education: logarithm of the median household income within the zip code in which the beneficiary lived, and educational level (percentages of residents in the zip code who had not completed high school, had completed high school only, and had attended or completed college).

Nearest Neighbor 1:5 Matching

We used nearest neighbor 1:5 matching with replacement, restricting the difference in propensity scores to be within .001. When using 6 to 9 months post MI as a window for readmission, we had 7264 cases and 68,074 potential controls. We were able to match 6864 cases. Our final sample included these 6864 cases and 33,726 controls. (We had 404 cases with fewer than 5 controls). When using 9 to 12 months post MI as the window for readmission, we had 5377 total cases and 61,500 potential controls. We were able to match 5184 cases and our final sample includes these 5184 cases and 25,843 controls.

Measurement of Adherence

We calculated 6-month adherence by tracing back from the readmission date for 6 months. Because the control group did not have a readmission date, we traced back from the anchor date, defined above, for 6 months to determine 6-month adherence. In addition, we constrained beneficiaries to be continuously enrolled in a stand-alone Part D plan during the 6-month MPR measurement periods. As a result, the total sample size dropped from 40,590 to 40,245 for the 6-to-9-month readmission window, and from 31,027 to 30,265 for the 9-to-12-month readmission window.

Two adherence measures were created: 1 for betablockers and the other for all 3 subclasses used to treat MI (beta-blockers, statins, and ACE inhibitors/ARBs). We measured adherence for only beta-blockers separately because the 6-month persistent use of beta-blockers post MI is a Healthcare Effectiveness Data and Information Set (HEDIS) quality measure. We did not measure adherencefor aspirin because aspirin is usually purchased over the counter and is not included in Part D claims data.

Adherence was measured by MPR, defined as the ratio of days of supply of medication the patient had in possession (numerator) over the number of days in the measurement period multiplied by the number of medications prescribed (denominator). Since we include several different medications into 1 MPR measurement, we only count medications in the denominator after the initial prescription following hospital discharge. For example, suppose a patient filled her first beta-blocker prescription on January 1, 2008, and her first ACE inhibitor prescription on February 1, 2008. Her MPR would be the number of betablocker pills in the first month divided by 30, while her MPR for the subsequent months would be her number of beta-blocker pills plus the number of ACE inhibitor pills divided by 60.

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up